Luye Pharma Group Ltd
Research Luye Pharma Group Ltd (LUP) on Bullrun: market cap EUR 843.28M, P/E 10.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLUP
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 843.28M
- P/E10.4
- Financial periodFY2024
- RevenueEUR 6.06B
- Revenue growth-1.3%
- Net incomeEUR 471.89M
- Free cash flow-EUR 1.54B
- Gross margin66.7%
Valuation Snapshot
latest market cap is EUR 843.28M; P/E is 10.4.
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia.
Frequently asked questions
What is Luye Pharma Group Ltd's market cap?
Luye Pharma Group Ltd's market capitalization is EUR 843.28M.
What is Luye Pharma Group Ltd's P/E ratio?
Luye Pharma Group Ltd's price-to-earnings (P/E) ratio is 10.4.
What does Luye Pharma Group Ltd do?
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary;